Literature DB >> 24036550

Atypical heterochromatin organization and replication are rapidly acquired by somatic cells following fusion-mediated reprogramming by mouse ESCs.

Karen E Brown1, Hakan Bagci, Jorge Soza-Ried, Amanda G Fisher.   

Abstract

We recently reported that mouse embryonic stem cells (ESCs) in S/G 2 are more efficient at reprogramming somatic cells than ESCs at other stages of the cell cycle. We also provided evidence that DNA replication is induced in the nuclei of somatic partners upon fusion with ESC partners, and showed that this was critical for their conversion toward a pluripotent state. (1) Here we have used counterflow centrifugal elutriation to enrich for ESCs at different cell cycle phases, so as to examine in detail the properties of S/G 2 phase cells. This revealed that the replication and organization of DAPI-intense heterochromatin in ESCs is unusual in two respects. First, replication of heterochromatin occurred earlier during S phase and was associated with precocious H3S10 phosphorylation. Second, heterochromatin protein 1 α (HP1α), which invariably marks DAPI-intense and H3K9me3-enriched pericentromeric domains in mouse somatic cells, (2) was not necessarily associated with these H3K9me3-enriched domains in undifferentiated ESCs. These data, which complement recent replication timing (3) and electron spectroscopic imaging (ESI) analyses, (4) suggest that heterochromatin is atypical in ESCs. Interestingly, as these unusual features were rapidly acquired by somatic nuclei upon ESC fusion-mediated reprogramming, our results suggest that fundamental changes in cell cycle structure and heterochromatin dynamics may be important for conferring pluripotency.

Entities:  

Keywords:  elutriation; heterochromatin; heterokaryon; pluripotency; replication; reprogramming

Mesh:

Substances:

Year:  2013        PMID: 24036550      PMCID: PMC3885636          DOI: 10.4161/cc.26223

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  44 in total

1.  Specificity of the HP1 chromo domain for the methylated N-terminus of histone H3.

Authors:  S A Jacobs; S D Taverna; Y Zhang; S D Briggs; J Li; J C Eissenberg; C D Allis; S Khorasanizadeh
Journal:  EMBO J       Date:  2001-09-17       Impact factor: 11.598

2.  Regulation of APC/C (Cdh1) ubiquitin ligase in differentiation of human embryonic stem cells.

Authors:  Ortal Bar-On; Ma'anit Shapira; Karl Skorecki; Avram Hershko; Dan D Hershko
Journal:  Cell Cycle       Date:  2010-05-15       Impact factor: 4.534

3.  Dynamic regulation of effector protein binding to histone modifications: the biology of HP1 switching.

Authors:  Holger L Dormann; Boo Shan Tseng; C David Allis; Hironori Funabiki; Wolfgang Fischle
Journal:  Cell Cycle       Date:  2006-12-15       Impact factor: 4.534

Review 4.  Histone acetylation and transcriptional regulatory mechanisms.

Authors:  K Struhl
Journal:  Genes Dev       Date:  1998-03-01       Impact factor: 11.361

5.  Chromatin-interaction compartment switch at developmentally regulated chromosomal domains reveals an unusual principle of chromatin folding.

Authors:  Shin-ichiro Takebayashi; Vishnu Dileep; Tyrone Ryba; Jonathan H Dennis; David M Gilbert
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-17       Impact factor: 11.205

6.  Evidence for the existence of an HP1-mediated subcode within the histone code.

Authors:  Gwen Lomberk; Debora Bensi; Martín E Fernandez-Zapico; Raul Urrutia
Journal:  Nat Cell Biol       Date:  2006-03-12       Impact factor: 28.824

7.  DNA synthesis is required for reprogramming mediated by stem cell fusion.

Authors:  Tomomi Tsubouchi; Jorge Soza-Ried; Karen Brown; Francesco M Piccolo; Irene Cantone; David Landeira; Hakan Bagci; Helfrid Hochegger; Matthias Merkenschlager; Amanda G Fisher
Journal:  Cell       Date:  2013-02-14       Impact factor: 41.582

8.  Geminin escapes degradation in G1 of mouse pluripotent cells and mediates the expression of Oct4, Sox2, and Nanog.

Authors:  Valerie S Yang; Stephanie A Carter; Sarah J Hyland; Kikuë Tachibana-Konwalski; Ronald A Laskey; Michael A Gonzalez
Journal:  Curr Biol       Date:  2011-04-14       Impact factor: 10.834

9.  Replication timing: a fingerprint for cell identity and pluripotency.

Authors:  Tyrone Ryba; Ichiro Hiratani; Takayo Sasaki; Dana Battaglia; Michael Kulik; Jinfeng Zhang; Stephen Dalton; David M Gilbert
Journal:  PLoS Comput Biol       Date:  2011-10-20       Impact factor: 4.475

10.  Heterokaryon-based reprogramming of human B lymphocytes for pluripotency requires Oct4 but not Sox2.

Authors:  Carlos F Pereira; Rémi Terranova; Natalie K Ryan; Joana Santos; Kelly J Morris; Wei Cui; Matthias Merkenschlager; Amanda G Fisher
Journal:  PLoS Genet       Date:  2008-09-05       Impact factor: 5.917

View more
  4 in total

1.  Rapamycin induces pluripotent genes associated with avoidance of replicative senescence.

Authors:  Tatiana V Pospelova; Tatiana V Bykova; Svetlana G Zubova; Natalia V Katolikova; Natalia M Yartzeva; Valery A Pospelov
Journal:  Cell Cycle       Date:  2013-12-02       Impact factor: 4.534

2.  Characterization and dynamics of pericentromere-associated domains in mice.

Authors:  Patrick J Wijchers; Geert Geeven; Michael Eyres; Atze J Bergsma; Mark Janssen; Marjon Verstegen; Yun Zhu; Yori Schell; Carlo Vermeulen; Elzo de Wit; Wouter de Laat
Journal:  Genome Res       Date:  2015-04-16       Impact factor: 9.043

3.  "Stealth dissemination" of macrophage-tumor cell fusions cultured from blood of patients with pancreatic ductal adenocarcinoma.

Authors:  Gary A Clawson; Gail L Matters; Ping Xin; Christopher McGovern; Eric Wafula; Claude dePamphilis; Morgan Meckley; Joyce Wong; Luke Stewart; Christopher D'Jamoos; Naomi Altman; Yuka Imamura Kawasawa; Zhen Du; Loren Honaas; Thomas Abraham
Journal:  PLoS One       Date:  2017-09-28       Impact factor: 3.240

4.  Macrophage-tumor cell fusions from peripheral blood of melanoma patients.

Authors:  Gary A Clawson; Gail L Matters; Ping Xin; Yuka Imamura-Kawasawa; Zhen Du; Diane M Thiboutot; Klaus F Helm; Rogerio I Neves; Thomas Abraham
Journal:  PLoS One       Date:  2015-08-12       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.